Aberrant functioning of kinases is known to be an important driver in cancer. Targeting hereof has proven to be extremely successful and has already revolutionized the management of numerous types of cancer.
At Crossfire Oncology we approach kinases from three different angles: inhibitors, degraders, and degrader antibody conjugates. This tailored approach allows us to design kinase targeting drugs that aim to maximize the therapeutic benefit for cancer patients.
Company Details
- Employees
- 15
- Founded
- 2021
- Address
- Kloosterstraat 9, Oss,brabant 5349ab,netherlands
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- HQ
- Oss, Brabant
Crossfire Oncology Questions
Crossfire Oncology's website is http://www.crossfire-oncology.com
Crossfire Oncology's LinkedIn profile is https://nl.linkedin.com/company/crossfire-oncology
Crossfire Oncology has
15 employees.
View email and phone details for 15
employees at Crossfire Oncology.
Crossfire Oncology's industry is
Biotechnology Research
Crossfire Oncology's top competitors are
Organon,
Synaffix,
Ardena,
Ipa (Immunoprecise Antibodies),
Byondis,
Pivot Park,
Oncolines B.v.,
Symeres,
Ribopro,
Acerta Pharma B.v. (A Member Of The Astrazeneca Group).
Crossfire Oncology's categories are Biotechnology Research
Crossfire Oncology's founding year is 2021
